Compare Flagstar Bank NA (FLG) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Flagstar Bank NA vs Incyte Corporation — how do they compare? Flagstar Bank NA trades at $14.2 (market cap $5.89B), while Incyte Corporation trades at $121.06 (market cap $24.54B). The key difference: Incyte Corporation is far larger — about 4.2× Flagstar Bank NA's market cap, and Flagstar Bank NA pays a 0.28% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| FLG | INCY | |
|---|---|---|
Market Cap | $5.89B | $24.54B |
Sector | Financials | Health |
52-Week High | $15.36 | $129.93 |
52-Week Low | $10.72 | $81.61 |
Dividend Yield | 0.28% | — |
Enterprise Value | — | $20.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLG trades at $14.21, up 1.43% today, with a bullish technical signal from moving averages. The stock shows a low P/B of 0.77 but a high P/E of 473, reflecting recent profitability after a 2025 net loss. Recent Q2 2026 earnings missed estimates, but the company announced a $250 million share repurchase program and declared dividends, signaling financial strength. Analyst consensus is a Buy with a $16.85 price target, indicating potential upside from current levels.
The outlook is cautiously optimistic, supported by analyst bullishness and strategic initiatives like technology transformation. Key risks include earnings volatility, competitive pressures in banking, and macroeconomic sensitivity. The stock presents a value opportunity based on price-to-book, but sustained earnings growth is crucial for justifying the elevated P/E ratio.
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Flagstar Bank NA
Flagstar Bank is a prominent US financial institution and a subsidiary of New York Community Bancorp. It provides commercial banking, mortgage services, and diverse personal finance products.
Read more on FLG →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
